within Pharmacolibrary.Drugs.ATC.G;

model G04BD04
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.06,
    Cl             = 0.0008333333333333334,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.262,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005,
    Tlag           = 600,            
    Vdp             = 0.049,
    k12             = 25,
    k21             = 25
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G04BD04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Oxybutynin is an antimuscarinic agent used primarily to treat symptoms of overactive bladder, such as urinary urgency, frequency, and urge incontinence. It works by relaxing the bladder smooth muscle. Oxybutynin is approved and widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after a single oral dose (5 mg tablet).</p><h4>References</h4><ol><li><p>Krause, P, et al., &amp; Rubenwolf, P (2013). Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study. <i>The Journal of urology</i> 190(5) 1791–1797. DOI:<a href=\"https://doi.org/10.1016/j.juro.2013.05.011\">10.1016/j.juro.2013.05.011</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23669567/\">https://pubmed.ncbi.nlm.nih.gov/23669567</a></p></li><li><p>Baldwin, CM, &amp; Keating, GM (2009). Transdermal oxybutynin. <i>Drugs</i> 69(3) 327–337. DOI:<a href=\"https://doi.org/10.2165/00003495-200969030-00008\">10.2165/00003495-200969030-00008</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19275276/\">https://pubmed.ncbi.nlm.nih.gov/19275276</a></p></li><li><p>Douchamps, J, et al., &amp; Herchuelz, A (1988). The pharmacokinetics of oxybutynin in man. <i>European journal of clinical pharmacology</i> 35(5) 515–520. DOI:<a href=\"https://doi.org/10.1007/BF00558247\">10.1007/BF00558247</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3234461/\">https://pubmed.ncbi.nlm.nih.gov/3234461</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G04BD04;
